South Dakota expects to save about $750,000 a year after choosing three drugs for international benchmark pricing through Medicaid, according to a state announcement issued Friday, Sept. 18.
The decision places the state in the federal GENEROUS Model, a five-year demonstration that uses supplemental manufacturer rebates to align Medicaid’s net cost for selected medicines with prices paid in certain other countries. The state has not publicly identified the three drugs, so beneficiaries should not assume every prescription or pharmacy charge will change.
CMS said all 50 states, the District of Columbia and Puerto Rico applied, while 40 states and Puerto Rico had signed participation agreements by Sept. 18. The agency projects $64.3 billion in taxpayer savings over 10 years across participating jurisdictions. That national estimate is not the same as South Dakota’s forecast; the state’s own figure is approximately $750,000 annually.
How the savings mechanism works
Participating manufacturers will offer supplemental rebates that bring the net Medicaid price of covered outpatient drugs closer to selected international prices. States invoice manufacturers quarterly, and CMS monitors pricing accuracy while adjusting the federal share of Medicaid payments, the model design says.
Participation does not force South Dakota to accept the arrangement for every eligible drug. CMS says states may make individual drug choices based on whether the new price is better after existing rebates, whether comparable medicines cost less and whether an existing supplemental-rebate contract remains preferable. Manufacturers also negotiate standardized coverage criteria with CMS, meaning the state must consider both price and access terms before opting in.
That distinction matters for patients. The program is principally a rebate model between manufacturers and Medicaid agencies; it is not a blanket retail-price cap. CMS says lower state costs may improve access and preserve funds for other Medicaid services, but the practical effect depends on which products South Dakota ultimately includes and what coverage rules accompany them.
What happens next
CMS launched GENEROUS in January 2026 and says it will run for five years. The agency’s Sept. 18 update gives states that have not finalized agreements until Sept. 30 to sign.
South Dakota officials have already analyzed candidate drugs and estimated savings, the state release indicates, but it does not publish implementation dates, product names, beneficiary counts or projected savings by drug. Those details will determine whether the program primarily changes state spending, expands access, or both.
The model builds on the Medicaid Drug Rebate Program, under which manufacturers provide statutory rebates in exchange for state coverage. CMS reported net Medicaid prescription-drug spending of $60 billion in 2024, up $10 billion from 2022, when it launched GENEROUS.
For South Dakota residents, the most useful near-term test is not the headline savings estimate but the state’s forthcoming list of drugs and coverage criteria. Until those are released, Medicaid members should continue using current benefits and confirm coverage through their usual plan or pharmacy channels.
